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Summary: Flow cytometric DNA analysis and PCNA/AgNOR 
sequential staining were performed to examine the pattern of 
recurrence in non-small cell lung cancer. 
The DNA ploidy was aneuploidy in 80.6% and diploidy in 19.4%. The 
mean DNA index (DI) was 1.63 for the total population, 1.62 in 
non-recurrent cases, and 1.64 in recurrent cases. The differences were 
not statistically significant, but the distribution pattern of DIs was 
somewhat at odds between non-recurrent cases and recurrent cases. 
In the analysis of recurrence in Stage I and II, the lung metastasises or 
the local recurrences were concentrated in the lower DI range, and 
the brain or the bone metastasises in the higher DI range. Thus, cases 
with DIs under 1.3 showed the lung metastasises or the local 
recurrences, and those over 1.9 were in the brain or the bone, but the 
cases with DI from 1.3 to 1.9 had all types of recurrences. 
The AgNOR scores obtained by sequential staining with PCNA 
provided more accurate information on recurrences. The cases with 
any DI and lower AgNOR scores (under about 3.0) in PCNA-negative 
cells showed rare recurrences. In the DI range of 1.3 to 1.9, many 
cases with AgNOR scores from 3.0 to 4.1 in PCNA-negative cells had 
the lung metastasises or the local recurrences, and those with AgNOR 
scores over 4.1 had those in the brain or the bone. 
The above information is considered valuable for the follow-up and 
postoperative management of Stage I and II non-small cell lung 
carcinoma.
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Introduction 
Non-small cell lung cancer (NSCLC), which is an increas-
ing important cause of death in both men and women in 
Japan. It represents a mixed group of tumors varying in 
clinical behavior and in the response to different treatment 
modalities. The factor most predictive of the clinical out-
come is the stage (TNM classification of UICCI') at diag-
nosis. However, the patients may undergo absolute curative 
operation or relative curative operation, but, even if the 
diagnosis is Stage I, over 20 or 30% of them will die from 
relapses within five years after operation.') Great variabil-
ities in outcome in each stage demand a search for some 
other prognostic variables that would help distinguish 
between patients with good prognosis from those with poor
prognosis. 
 The flow cytometric analysis of the nuclear DNA con-
tents has been used to establish objective prognostic vari-
ables in a wide variety of neoplasms.3-5' Regarding NSCLC, 
there are some reports that DNA ploidy has an important 
prognostic value."') We also reported that DNA ploidy was 
a useful prognostic variable predictive of the postoperative 
courses of Stage I and II cases, permitting further ramifi-
cation of Stage I and II diseases.") 
 The scoring of interphase nucleolar organizer regions 
(NORs) using the argyroghil (AgNOR) technique") has 
been demonstrated to be of value in assessing the degree of 
malignancy in neoplasms.1 19) Cancer cells are charac-
terized by higher AgNOR numbers in the interphase 
nucleus than in normal or benign tumor cells. And in terms 
of malignancy, high grade malignant cells have higher 
AgNOR numbers than the lower grade ones. Initially, the 
reason for increased AgNOR counts with increasing de-
grees of malignancy was not fully understood but there is 
now a profusion of evidence showing that the AgNOR 
score in interphase nuclei represents the level of cell 
proliferation. The proliferating cell nuclear antigen (PCNA) 
has attracted attention as a marker of proliferating cells. 
With anti-PCNA antibodies unlike Ki-67 and thymidine- or 
bromodeoxyuridine-labeling, the immunohistochemical 
cell-cycle can be analyzed in routinely processed formalin-
fixed and paraffin-embedded tissues. The double staining 
method using monoclonal antibodies in combination with 
the. argyrophil technique"' has helped to overcome the 
problem associated with the heterogeneity of neoplasms by 
allowing differentiation of various cells before AgNORs 
counting. We applied this method to NSCLC using PCNA. 
 In this study, we performed a flow cytometric DNA 
analysis, especially for DNA index (DI), and PCNA and 
AgNOR sequential staining, and studied, in NSCLC, the 
correlation between these parameters and recurrence.
Materials and Methods 
Patients 
The study population consisted of 320 patients who were 
diagnosed and treated for NSCLC at the First Department 
of Surgery, Nagasaki University School of Medicine during 
the period of 1982 to 1988. The morphological classi-
fication used was that of the WHO`) study. Postsurgical 
histopathologic findings (TNM) and postsurgical TNM 
staging (pathologic stage) were based on the UICC classi-
fication. The tumors, totaling 320, were determined to be 
squamous cell carcinoma in 145, adenocarcinoma in 158, 
large cell carcinoma in 12, and other carcinomas in 5. Of 
320 patients, 163 were classified into Stage I, 27 into Stage 
II, 130 into Stage III, Stage IV cases were not included in 
this study. 
DNA Flow Cytometry 
At least 3 representative tumor blocks from each case, 
which included the least differentiated portion of the tumor, 
were used for flow cytometric analysis. As much as pos-
sible, sections with no or minimal tumor necrosis were 
selected. 
  Tissues for flow cytometric analysis were processed by 
the method of Schutte et al."' as modified. Briefly, 2 or 3 
sections, 50,um thick, were cut out from each formalin-
fixed and paraffin-embedded block. The tissues were depa-
raffinized in xylene and rehydrated in an ethanol series. 
Each sample was taken to distilled water and incubated in a 
0.25% solution of trypsin (DIFCO, 1:250, Detroit, Mich.) 
in citrate buffer (3mM trisodium citrate, 0. 1% v/v Nonidet 
P-40, 1.5mM spermine tertachloride, 0.5mM Tris. pH 7.6) 
at 37 °C for 18 hours on a shaking-water bath. The trypsin-
digested sample was filtered through a 50,um nylonmesh 
and centrifuged. It was then stained with propidium iodide 
solution (final concentration 50,ug/ml, Sigma Chemical 
Co., St. Louis, MO) according to the method of Vindelgv 
et al."' 
  An average of 10,000 nuclei per sample were analyzed 
on a FACScan flow cytometer (Becton-Dickinson, FACS 
Division, San Jose, CA). The Non-neoplastic lung tissue 
included in each specimen served as an internal standard. 
 The generated flow cytometric data were classified into 
DNA diploidy and DNA aneuploidy. The DNA diploid 
tumor population was defined as having only one G0/G, 
peak. DNA aneuploidy was assumed when a GQ/G, peak 
was accompanied by S and G2M. The DNA content was 
expressed in DI. Accounting for intratumoral DNA hetero-
geneity, the highest DI was regarded as the DNA content of 
each case. The half-peak coefficient of variation (CV) was 
calculated for DNA diploid Go/G, peaks in all cases, which 
averaged 5.4% (range, 1.3% to 9.9%). Histograms with CV 
exceeding 8% were considered as poor quality and were
not used. 
PCNA and AgNOR Sequential Staining 
Sequential staining of PCNA and AgNOR was performed 
according to the method of Yoshida," and a modification 
of the method of Smith et al."' In brief, formalin-fixed and 
paraffin-embedded tissue sections, 3,um thick, were taken 
from the same block just as for DNA analysis and allowed 
to adhere to glass slides at room temperature. The sections 
were then dewaxed in xylene, rehydrated in an ethanol 
series, and taken to distilled water. 
  The sections were incubated in. a 1:100 dilution of mouse 
monoclonal anti-PCNA antibody (PC 10, DAKO) in PBS 
(pH 7.6) for the use as primary antibody. PCNA was 
visualized using the labelled streptavidin biotin alikaline 
phoshatase method (DAKO LSAB Kit [AP], DAKO) and 
Fast red (DAKO). 
 After 10 minutes' washing in distilled deionized water, 
the standard AgNOR staining using an AgNORs staining 
colloid (1 volume of 2% gelatin in 1% formic acid and 2 
volumes of 50% silver nitrate solution) was performed."-"' 
However, the incubation at room temperature was carried 
out for an extended period of 50 minutes for improved 
contrast in the dark room. The sections were immersed in 
5% sodium thiosulfate solution for 30 or 60 seconds, 
washed in distilled water for 10 minutes, and mounted in 
aqueous mounting medium. 
 The nucleus was regarded as being PCNA-positive only 
when there was an unequivocal, intense red reaction prod-
uct. More than 1,000 cells were examined under a x40 
objective and the PCNA labelling index (PCNA LI) was 
determined. Then, AgNORs were counted in 100 each of 
random PCNA-positive, and PCNA-negative cells, under 
an X 100 oil immersion objective, said number having been 
achieved by the standard continuous mean technique. 
Statistical Analysis 
The association between different categories of DNA flow 
cytometric data was examined using Student's t-test. The 
differences between PCNA scores in different groups of 
specimens and between AgNOR counts in different cell 
groups were analyzed by the confidence interval procedure.
Results 
Clinical and Histopathological Characteristics 
Histograms that could be analyzed were obtained in 288 of 
the 320 cases included in this study. The clinical and 
histopathologic characteristics and survival rates of the 
excluded cases did not differ significantly from those of the 
whole population.
 The patient population consisted of 225 men and 63 
women. They were between 31 and 85 years of age (mean 
± standard deviation, 64.0 ± 9.36 years). There were 138 
squamous cell carcinomas (47.9%), 136 adenocarcinomas 
(47.2%), 9 large cell carcinomas (3.1%), and 5 other 
carcinomas (1.8%). TNM staging using postsurgical patho-
logic criteria yielded the following groups: 145 tumors of 
Stage I; 24 of Stage II; and 120 of Stage III. 
  One-hundred-and-one (35.1%) of those 288 patients had 
recurrences. There were 30 (29.7%) in the lung metas-
tasises, 21 (20.8%) in the local recurrences, 19 (18.8) in the 
brain, 13 (12.9%) in the bone, and 18 (17.8%) in others. No 
relationship was found between the site of recurrence and 
TNM Stage. However, histopathologically, more cases of 
metastasises in the brain were adenocarcinomas and more 
of the local recurrences were squamous cell carcinomas. 
Flow Cytometric Analysis 
Of the 288 tumors that were successfully analyzed, 232 
(80.6%) were DNA aneuploid and 56 (19.4%) were DNA 
diploid. The CV for diploid G0/G, peaks for all cases 
ranged form 1.3 to 9.9 (median, 5.4). As indicated in Table 
1, some statistically significant differences were found 
between the patients with diploid tumors and those with 
aneuploid tumors in clinical and histologic variables (stage 
and nodal status). In contrast, histological types were not 
associated with DNA ploidy. 
 The histogram of DI distribution in all cases is shown in 
Fig. 1; the mean DI value was 1.63, or 1.55 in Stage I, 1.73 
in Stage II, and 1.71 in Stage III. The difference was 
statistically significant between Stages I and 11, and be-
tween Stages I and III (p < 0.01). In terms of histologic 
type, the mean DI values in squamous cell carcinoma, 
adenocarcinoma, large cell carcinoma, and others were 
1.60, 1.66, 1.87, and 1.31, respectively. These differences
Table 1. Relationship of Clinicopathological Features with DNA 
Ploidy.
               Diploidy Aneuploidy Total Mean DI             (%) (%) 
Type of carcinoma N. S. 
  Squamous 29 (21.0) 109 (80.0) 138 1.60 
 Adeno 25 (18.4) 111 (81.6) 136 1.66 
 Large cell 1 (11.1) 8(88.9) 9 1.87 
 Others 1 (20.0) 4(80.0) 5 1.30 
Stage p < 0.01 
 1 42 (30.0) 103 (70.0) 145 1.55 
 II 3(12.5) 21 (87.5) 24 1.73 
1  III 11 ( 9.2) 108 (90.8) 119 1.71 
T factor N. S. 
  1 25 (31.3) 55 (68.7) 80 1.59 
 2 23 (15.5) 125(84-5) 148 1.62 
 3 6(13.3) 39 (86.7) 45 1.73 
 4 2(13.3) 13 (86.7) 15 1.66 
N factor p < 0.05 
 0 45 (26.6) 124 (73.4) 169 1.57 
  1 4(12.5) 28 (87.5) 32 1.72 
 2 7 ( 8.4) 76 (91.6) 83 1.68 
 3 0 4(100) 4 2.13 
DI: DNA index 
N. S.: Not significant
were not statistically significant. 
  With regard to recurrence, the mean DI value was 1.64 
in recurrent cases (RC), 1.62 in non-recurrent cases (NRC), 
and 1.63 in all cases. There were no statistically significant 
differences but the distribution patterns showed some dif-
ferences. Thus, the pattern for all cases showed both DNA 
diploidy and DNA aneuploidy peaks, while only the DNA 
aneuploid peak was found in RC (Fig. 2). 
  Recurrence site analysis was made from DI distributions 
for 4 types of recurrence, viz. the lung, the local, the brain 
and the bone. The mean DI values of recjirrence in the 
lung, the local, the brain and the bone were 1.56, 1.57, 
1.83, 1.80, respectively (Fig. 3A). The difference between
Fig. 1. Distribution of DIs in NSCLC; (A) in Stage I, II, and III, and (B) in squamous cell, adeno-, large-cell, and other carcinomas.
Fig. 2. Distibution of DIs in recurrence and non-recurrence cases.
recurrences in the lung and the local and those in the brain 
and the bone was statistically significant (p < 0.05). The 
DIs of recurrences in the lung and the local were concen-
trated in the lower DI range, while the DIs of recurrences 
in the brain and the bone were concentrated in the higher 
DI range with the exception of DNA diploidy (DI = 1.0). In 
Stages I and II, this tendency was more prominent. The 
mean DIs for the lung, the local, the brain and the bone 
were 1.40, 1.48, 1.73 and 2.08, respectively (p < 0.005, 
Fig. 3B). 
 The DI distribution pattern of RC was reconstructed 
according to 2 types of recurrence, i. e. intra-lung recur-
rence (ILR, lung and local) and extra-lung recurrence 
(ELR, brain and bone) in Fig. 4. The cases of DI under 1.3 
showed only ILRs, and those of DI over 2.0 invariably had 
ELRs. In the cases with DI from 1.3 to 2.0, all types of 
recurrences were found. 
PCNA and AgNORs Sequential Staining Analysis 
We used cases in Stages I and II (n = 55) for sequential 
staining in this study. A positive reaction to PCNA anti-
body was reflected in an intense red coloration of the 
nucleus. The AgNORs showed up as black "dots" of 
varying size. 
 The mean AgNOR scores in staining AgNOR alone were 
different between Stage I/II and Stage III (4.58 versus 5.83,
p < 0.0005, data was not shown). However, no difference 
between NRC and RC in Stages I and II (Table 2). The 
mean PCNA LI showed no significant difference, either. 
 The difference in AgNOR score between PCNA-positive 
and-negative cells were statistically significant at p < 
0.0001. The mean AgNOR score of PCNA-positive cells 
was 6.67 in NRC (n = 11) versus 7.52 in RC (n = 44), 
although this difference was not statistically significant. A 
statistically significant difference was found between NRC 
and ELR (6.67 versus 8.44, p < 0.001). The AgNOR score 
of PCNA-negative cells was 2.98 in NRC versus 3.96 in 
RC, 2.98 in NRC versus 3.67 in ILR, 2.98 in NRC versus 
4.42 in ELR, and 3.67 in ILR versus 4.42 in ELR. These 
differences were statistically significant. 
Correlation between DI and Sequential Staining 
The correlation between DI and AgNOR score in PCNA-
negative cells in Stages I and II are shown in a scatter 
diagram (Fig. 5). There was no correlation between DI and 
AgNOR score in any type of cell (AgNOR alone, PCNA-
positive cells, and PCNA-negative cells), or between DI 
and PCNA LI. 
 The cases with AgNOR scores under 3.0 were mostly 
non-recurrence cases except one, and all the cases with 
AgNOR scores over 3.0 and DI under 1.3 were ILR cases. 
Most of the cases with AgNOR scores over 4.1 and DI over
Fig. 3. Distribution of DNA indices in recurrent cases. (A) Distribution of DIs of each recurrent type in all recurrent cases. (B) 
Distribution of DIs of each rerurrent type in Stage I and II recurrent cases. The DIs of the lung and the local are concentrated in the lower 
DI range, while the DIs of the brain and the bone in higher DI range with the exception of DNA diploidy (DI = 1.0).
Fig. 4. Distribution of DIs Stage I and II recurrent cases. The types of recurrence are recategorized into ILRs (lung and local) and ELRs 
(brain and bone). The cases with DI < 1.3 show IRLs only, and those with DI > 1.9 show ELRs only. In the case of 1.3 < DI < 1.9, all 
types of recurrences are found.
Table 2. Relationship of Recurrence with AgNOR Scores in PCNA-positive and -negative Cells in Stage I and II Non-Small Cell Lung 
Cancers.
                        Mean AgNOR score in PCNA LI Mean AgNOR score in Mean AgNOR score in 
                      AgNOR staining only (%) PCNA positive cells PCNA negative cells
 All cases (n = 55) 4.56 ± 1.08 60.0 7.42 ± 1.43 3.77 ± 0.77 
 Non-recurrence (n = 11) 4.94± 1.15 59.2 6.67 ± 0.96 2.98 ± 0.64*--] 
 Recurrence (n = 44) 4.49 ± 0.88 61.2 7.52 ± 1.53 * * * 3.96 ± 0.71 * 
     ILRs (n = 21) 4.10± 0.88 62.3 6.96 ± 1.62 3.67 ± 0.73 
     ELRs (n = 15) 5.03 ± 0.90 59.6 8.44 ± 0.97 4.42 ± 0.45 
PCNA LI: PCNA labelling index 
ILRs: intra-lung recurrences (lung and local) 
ELRs: extra-lung recurrences (brain and bone) 
* p < 0.05, ** p < 0.005, *** p < 0.001, **** p < 0.0001
Fig. 5. Correlation between DI and AgNOR score in PCNA-negative cells in Stages I and II.
1.3 had ELRs, but some cases with AgNOR scores from 
3.0 to 4.1 and DI from 1.3 to 1.9 did not show recurrences 
or had ELRs in spite of the prediction of ILR.
Discussion 
Though a number of flow cytometric studies have so far 
been done on DNA ploidy in NSCLC, the significance of 
DNA ploidy as a prognostic variable has not been estab-
lished. Some studies found no correlation between DNA 
ploidy and clinical outcome""' but many studies showed 
DNA aneuploidy to be highly predictive of an unfavorable 
outcome."' Our previous study (Tagawa et al.") indicated
that the DNA ploidy was a useful prognostic variable 
capable of predicting the postopeative courses of Stage I 
and II cases and allowing a further division of Stage I and 
II diseases into subgroups. Therefore, in this study, we 
performed DI analysis mainly in Stage I and II cases, 
leaving the study of correlation between DI and clinical 
outcome, especially recurrence, to be completed in future. 
 The finding of 80.6% DNA aneuploidy in this series falls 
within the reported range of 45% to 85%. NSCLC shows a 
high frequency of DNA aneuploidy but some DNA aneu-
ploidy cases may meet with varying clinical outcomes. 
Meanwile, DI reflects the nuclear DNA content of the case 
and as such is used as a marker instead of DNA diploidy or 
aneuploidy. However, there is the problem of DNA hetero-
geneity, which has been found in NSCLC79' as well as in 
other neploasms.3033, In the present study, we sampled at 
least 3 tumor blocks to detect more stemlines, and when 
DNA heterogeneity was found, the highest DI value was 
taken as the DI of the case. 
 The rationale is as follows. The DI distribution was not 
alike between RC and NRC, although the mean DI value 
was almost compatible, viz. 1.64 versus 1.62. The DNA 
diploid (DI = 1.0) cases in RC were less numerous than 
those in NRC, and lower DI cases in RC were more 
numerous than those in NRC. In RC. the mode of recur-
rence was classified into 3 types according to DI in Stages I 
and II, and this mode classification suggested a new ap-
proach to the postoperative management of NSCLC. 
 The AgNOR score is being increasingly used in the field 
of tumor histology for assessing the degree of malignancy 
and sometimes for the prognosis and treatment of cases, 
too. Ogura et al."' reported that the number of AgNOR is 
related to the growth rate in lung adenocarcinoma, but 
some studies rule out any relation between AgNOR score 
and clinicopathological finding s.3 ,35' Thus, the AgNOR 
score had not been established as an independent param-
eter. Many investigators report that it is not recommendable 
to rely on any one histopathological marker of cell prolif-
eration but one should use a plurality of markers in combi-
nation for in improved accuracy of malignancy evaluation. 
Kakeji et al.3b' showed that the combined use of AgNOR 
and Ki-67 had a greater predictive value for lymph node 
metastasis in gastric cancer. 
 The possibilities of sequential staining using AgNOR in 
combination with a monoclonal antibody was first sug-
gested by Murray et al.") in 1989. In 1990, Janmohamed 
reported on the use of Ki-67 and AgNOR sequential stain-
ing in non-Hodgikin's lymphomas .3') The sequential stain-
ing method using PCNA and AgNOR was established by 
Yoshida,2) in colorectal carcinoma, Smith et al.,"' in non-
Hodgikin's lymphoma, almost at the same time. However, 
while PCNA immunostaining is theoretically indicated for 
cells in the late G, to S phase, PCNA is relatively stable and 
remains in nuclei till the G2 and M phase, in formalin-fixed 
and paraffin-embedded tissues. Therefore, we considered it 
worthwhile to use PCNA immunostaining for identification 
of the proliferation phase of the cells. We found the both 
PCNA-positive and -negative carcinoma cells had higher 
AgNOR numbers than normal lung tissue cells (data not 
shown). It is of interest that carcinoma cells lacking PCNA 
may still give relatively higher AgNOR scores compared 
with resting normal lung tissue cells. The AgNOR scores in 
PCNA-negative cells may be reflecting their proliferative 
activity even in the non-proliferating phase. 
 The results of the current study, indicated that DI is not 
so useful for the discrimination of recurrence from non-
recurrence, but in recurrent cases, DI can be instrumental 
for differentiating a mode of recurrence, for generally the 
lower DI cases had ILRs, the higher DI cases had ELRs,
and the intermediate DI cases develop all types of recur-
rences, particularly in Stages I and II. This information 
seems more useful than the information on DNA ploidy 
alone. 
 The DI and PCNA/AgNOR sequential staining data 
provided a greater insight into recurrences. The cases with 
any DI and lower AgNOR scores (almost under 3.0) in 
PCNA-negative cells develop recurrences rarely. When DI 
ranges from 1.3 to 1.9, many cases with AgNOR scores in 
PCNA-negative cells between 3.0 and 4.1 have ILRs, and 
those with AgNOR scores over 4.1 experience ELRs. 
 Considering the poor prognosis of NSCLS due to re-
lapses, which occur in Stage I cases, if the site of recur-
rence could be forecast and a timely prophylactic 
chemotherapy or radiation therapy for such episodes be 
instituted, the follow-up and selection of pertinent thera-
peutic approaches would be greatly facilitated, of course.
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